SATURDAY 9 OCTOBER 2021

PS2.1 Immune recognition of fungi: the writing on the wall

Neil Gow, United Kingdom, FECMM

PS2.2 Aspergillus fumigatus cell wall

Isabel Valsecchi, France

Top 10 Papers: Clinical / diagnostics / treatment

Don Sheppard, Canada, FECMM & Katrien Lagrou, Belgium, FECMM

Top 10 Papers: Basic / immunology / genomics

Julian Naglik, United Kingdom & Agostinho Carvalho, Portugal, FECMM

Q01 PCR based diagnosis of invasive mold infection

Maurizio Sanguinetti, Italy & Sean Zhang , USA

Q02 Recurrent Vulvovaginal Candidiasis (RVVC) - A diagnostic challenge

Riina Richardson, United Kingdom, FECMM & David Perlin, USA

Q03 Clinical Mycology- How to get things going in LMICs

Rita Oladele, Nigeria, FECMM & Bright Ocansey, Ghana

Q04 Management of candida in the ICU

Luis Ostrosky-Zeichner, USA, FECMM & Patricia Muñoz, Spain

Q05 Beta d glucan in paediatrics

Laura Ferreras-Antolin, United Kingdom & Thomas Lehrnbecher, Germany

Q06 Teaching Medical Mycology

Ester Segal, Israel, FECMM & June Kwon-Chung, USA

S05.1 Global epidemiology: What is changing, what is remarkable?

Rudramurthy Shivaprakash, India, FECMM

S05.2 How to determine MICs for my dermatophyte strain: Protocoles, tips, and trics

Sevtap Arikan Akdagli, Turkey, FECMM

S05.3 Primary immunodeficiencies and dermatophytoses: What else do we know?

Fanny Lanternier, France, FECMM

S05.4 Malassezia: epidemiology and host-response studies’

Dora Corzo-Leon, Scotland, United Kingdom

S05.5 Evaluation of the multiplex real-time PCR DermaGenius® assay for the detection of dermatophytes in hair samples from Senegal

Mouhamadou Ndiaye, Senegal

S06.1 How do Antibiotics Promote Susceptibility to Healthcare-Associated Fungal Infections?

Rebecca Drummond, United Kingdom

S06.2 Human genetic determinism of fungal diseases

Anna Puel, France

S06.3 Immunity to fungi in pneumocystis

Jay K Kolls, USA

S06.4 Serum proteins, crucial factors for human physiology that are exploited by Candida species to promote pathogenicity

Mark Gresnigt, Germany

S06.5 Increased efficacy of IL-18/posaconazole combination in a neutropenic animal model of pulmonary invasive aspergillosis by an azole resistant A.fumigatus isolate

Joseph Meletiadis, Greece

S07.1 Alternatives to drug treatment

Mihai Netea, the Netherlands

S07.2 Antifungal prophylaxis: Who, with what and how long?

Shmuel Shoham, USA

S07.3 Epidemiology

Shahid Husain, Canada, FECMM

S07.4 Side-effects and completion rates of universal versus targeted antifungal prophylaxis among lung transplant recipients 2010-2019

Cornelia Geisler Crone, Denmark

S07.5 Risk factors for and outcomes of invasive aspergillosis following kidney transplantation in the United States

Daniel Friedman, USA

S08.1 Diagnostic Value of Galactomannan in Bronchoalveolar Lavage Fluid for Chronic Respiratory Disease with Pulmonary Aspergillosis

Aleksandra Barac, Serbia, FECMM

S08.2 Underlying Conditions and Clinical Spectrum of Chronic Pulmonary Aspergillosis (CPA)

Eva Van Braeckel, Belgium

S08.3 Prevalence of chronic pulmonary aspergillosis in patients with tuberculosis

Felix Bongomin, Uganda, FECMM

S08.4 Prevalence of chronic pulmonary aspergillosis among active pulmonary tuberculosis patients with persisting symptoms in Uganda

Martha Namusobya, Uganda

S08.5 CPAepi: a study to investigate epidemiological characteristics of Aspergillus spp. isolated from CPA patients

Juan Carlos Soto Debran, Spain

S09.1 Distribution and Antifungal Susceptibility of yeasts causing invasive fungal diseases in China: An Update From the CHIF-NET Study

Yao Wang, China

S09.2 A global team effort - FungiScope

Danila Seidel, Germany, FECMM

S09.3 FUNGINOS – The Fungal Infection Network of Switzerland

Nina Khanna, Switzerland

S09.4 Update from ECMM and international registries: FungiScope Candida / CandiReg

Philipp Köhler, Germany, FECMM

S09.5 Epidemiology of Candida glabrata resistance in France and Germany within the frame of the ARest consortium

Alexandre Alanio, France, FECMM

S09.6 CPAnet: an International Chronic Pulmonary Aspergillosis Registry

Eva Van Braeckel, Belgium

Coffee break

S10.1 Diagnosis of Candida: Culture, Beta-glucan and Mannan

Liz Johnson, United Kingdom, FECMM

S10.2 The role of PCR and T2 MR

Cornelia Lass-Flörl, Austria, FECMM

S10.3 Mixed Yeast infections - Common or not?

Ana Alastruey-Izquierdo, Spain, FECMM

S10.4 Epidemiology and Clinical Burden of Candida infections across Europe - Results of ECMM Candida III

Martin Hoenigl, Austria, FECMM & Maiken Arendrup, Denmark

S11.1 The Lung mycobiom in health and disease

Paul Bowyer, United Kingdom

S11.2. Epidemiology of Fungal Infection in the ICU: Viral Infection a relevant risk factor?

Matteo Bassetti, Italy

S11.3 Mycobiome and invasive candidiasis

Tobias Hohl, USA, FECMM

S11.4 Mycobiome and microbial interactions

Ilse Jacobsen, Germany

S11.5 Development of a novel mycobiome diagnostic for fungal infection

Danielle Weaver, United Kingdom

S11.6 Effect of exposition to broad-spectrum antibiotics on the gut mycobiota of healthy volunteers

Margot Delavy, France

S12.1 Immunology

Frank van de Veerdonk, the Netherlands

S12.2 Definition, Diagnosis and Treatment of COVID-19 associated pulmonary aspergillosis - ECMM/ISHAM Consensus Guidance

Philipp Köhler, Germany, FECMM

S12.3 Covid associated mucormycosis'

Arunaloke Chakrabarti, India, FECMM

S12.4 Cytomegalovirus infection and invasive fungal disease

Monica Slavin, Australia

S12.5 ECMM CAPA Pulmonary aspergillosis in critically ill coronavirus disease 2019 patients– a multinational study

Juergen Prattes, Austria

S12.6 Immunological profiles of patients with influenza-associated pulmonary aspergillosis (IAPA)

Intan Dewi, the Netherlands

S13.1 Emergomyces

Nelesh Govender, South Africa, FECMM

S13.2 Emerging rare yeasts in outbreaks

Anuradha Chowdhary, India, FECMM

S13.3 Tracing patterns of evolution and acquisition of drug resistant Aspergillus fumigatus infection from the environment using population genomics

Matthew Fisher, United Kingdom

S13.4 EHA Guideline on antifungal prophylaxis in adult acute myeloid leukemia treated with novel agents

Jannik Stemler, Germany

S13.5 Candida auris clinical isolates from patients with COVID-19 in Saint Petersburg, Russia : identification, antifungal susceptibility

Ellina Oganesyan, Russia

S13.6 Hyperendemic zoonotic sporotrichosis: Implementation of a public health assistance service for human sporotrichosis in southern Brazil

Melissa Orzechowski Xavier, Brazil